Notes to editors
All comparators are for the 3 months to 31 March 2013 unless otherwise stated.
Income and expenses of foreign entities are translated at average exchange rates while their assets and liabilities are translated at the closing rates on 31 March 2014. The average rates employed in this announcement are 1 euro = £0.83 (3 months to 31 March 2013: 1 euro = £0.85) and CAD$1 = £0.55 (3 months to 31 March 2013: CAD$1 = £0.64).
Growth rates in the press release have been provided
in sterling terms unless stated otherwise. The following supplement presents this information on both a sterling and
constant currency basis.
Cautionary statements:
This should be read in conjunction with the documents filed by Aviva plc (the "Company" or "Aviva") with the United States Securities and Exchange Commission ("SEC"). This announcement contains, and we may make verbal statements containing, "forward-looking statements" with respect to certain of Aviva's plans and current goals and expectations relating to future financial condition, performance, results, strategic initiatives and objectives. Statements containing the words "believes", "intends", "expects", "projects", "plans", "will," "seeks", "aims", "may", "could", "outlook", "likely", "target", "goal", "guidance", "trends", "future", "projects", "estimates", "potential" and "anticipates", and words of similar meaning, are forward-looking. By their nature, all forward-looking statements involve risk and uncertainty. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. Aviva believes factors that could cause actual results to differ materially from those indicated in forward-looking statements in the presentation include, but are not limited to: the impact of conditions in the global financial markets and the economy generally , including exposure to financial and capital markets risks; the impact of simplifying our operating structure and activities; the impact of various local political, regulatory and economic conditions; market developments and government actions to address fiscal and budget constraints in the EU, UK and the US; the effect of credit spread volatility on the net unrealised value of the investment portfolio; the effect of losses due to defaults by counterparties, including potential sovereign debt defaults or restructurings, on the value of our investments; changes in interest rates that may cause policyholders to surrender their contracts, reduce the value of our portfolio and impact our asset and liability matching; the impact of changes in equity or property prices on our investment portfolio; fluctuations in currency exchange rates; the effect of market fluctuations on the value of options and guarantees embedded in some of our life insurance products and the value of the assets backing their reserves; the amount of allowances and impairments taken on our investments; the effect of adverse capital and credit market conditions on our ability to meet liquidity needs and our access to capital; a cyclical downturn of the insurance industry; changes in or inaccuracy of assumptions in pricing and reserving for insurance business (particularly with regard to mortality and morbidity trends, lapse rates and policy renewal rates), longevity and endowments; the impact of catastrophic events on our business activities and results of operations; the inability of reinsurers to meet obligations or unavailability of reinsurance coverage; increased competition in the UK and in other countries where we have significant operations; the effect of the European Union's "Solvency II" rules on our regulatory capital requirements; the impact of actual experience differing from estimates used in valuing and amortising deferred acquisition costs ("DAC") and acquired value of in-force business ("AVIF"); the impact of recognising an impairment of our goodwill or intangibles with indefinite lives; changes in valuation methodologies, estimates and assumptions used in the valuation of investment securities; the effect of legal proceedings and regulatory investigations; the impact of operational risks, including inadequate or failed internal and external processes, systems and human error or from external events; risks associated with arrangements with third parties, including joint ventures; funding risks associated with our participation in defined benefit staff pension schemes; the failure to attract or retain the necessary key personnel; the effect of systems errors or regulatory changes on the calculation of unit prices or deduction of charges for our unit-linked products that may require retrospective compensation to our customers; the effect of a decline in any of our ratings by rating agencies on our standing among customers, broker-dealers, agents, wholesalers and other distributors of our products and services; changes to our brand and reputation; changes in government regulations or tax laws in jurisdictions where we conduct business; the impact on our business and strategy due to proposed changes in UK tax law relating to annuities; the inability to protect our intellectual property; the effect of undisclosed liabilities, integration issues and other risks associated with our acquisitions; and the timing impact and other uncertainties relating to acquisitions and disposals and relating to other future acquisitions, combinations or disposals within relevant industries. For a more detailed description of these risks, uncertainties and other factors, please see Item 3D, "Risk Factors", and Item 5, "Operating and Financial Review and Prospects" in Aviva's Annual Report Form 20-F as filed with the SEC on 24 March 2014. Aviva undertakes no obligation to update the forward looking statements in this announcement or any other forward-looking statements we may make. Forward-looking statements in this presentation are current only as of the date on which such statements are made.
Aviva plc is a company registered in England No. 2468686.
Registered office
St Helen's
1 Undershaft
London
EC3P 3DQ
Page 6
Statistical Supplement
1 Basis of preparation
2. Trend analysis of VNB (continuing operations) - cumulative
3. Trend analysis of VNB (continuing operations) - discrete
4. Trend analysis of PVNBP (continuing operations) - cumulative
5. Trend analysis of PVNBP (continuing operations) - discrete
6. Trend analysis of PVNBP by product (continuing operations) - cumulative
7. Trend analysis of PVNBP by product (continuing operations) - discrete
8. Geographical analysis of regular and single premiums (continuing operations)
9. Trend analysis of investment sales - cumulative
10. Trend analysis of investment sales - discrete
11. Geographical analysis of regular and single premiums - investment sales
12. Trend analysis of general insurance and health net written premiums - cumulative
13. Trend analysis of general insurance and health net written premiums - discrete
Page 7
1 - Basis of preparation
The MCEV net asset value per share, VNB, PVNBP and operating capital generation (OCG) information included in this announcement and statistical supplement reflect the following changes to the MCEV methodology that have been implemented in 2014:
n The definition of covered business has been extended to include UK Retail Fund Management as well as health business in the UK and Singapore which is managed on a long term basis. Premiums for UK Retail Fund Management are now included in both investment sales and MCEV PVNBP. Premiums for long term health business in the UK and Singapore are now included in both IFRS net written premiums and MCEV PVNBP.
n The assessment of the liquidity premium is now based on a notional portfolio of assets for all business and for the first time a liquidity premium is applied to participating business. A liquidity premium continues to be applied to annuity business. The changes to the liquidity premium valuation impact the UK, Ireland, France, Italy and Spain.
Comparatives have been restated accordingly. The impact on MCEV net asset value per share, VNB, PVNBP and OCG is as follows:
n MCEV net asset value per share as at FY13 has increased from 445 pence per share to 463 pence per share;
n Total VNB from continuing operations for the three months ended 31 March 2013 increased from £196 million to £209 million, and for the year ended 31 December 2013 increased from £836 million to £904 million;
n Total PVNBP from continuing operations for the three months ended 31 March 2013 increased from £5,457 million to £5,898 million, and for the year ended 31 December 2013 increased from £20,548 million to £23,177 million;
n OCG for 1Q13 has remained stable at £0.4 billion.
For the Singapore health business, comparatives were not affected until the second half of 2013, when the product terms and conditions were changed enabling this business to be included as covered business.
2 - Trend analysis of VNB (continuing operations1) - cumulative
|
|
|
|
|
|
|
Growth3 on 1Q13 |
Gross of tax and non-controlling interests |
Restated2 1Q13 YTD £m |
Restated2 2Q13 YTD £m |
Restated2 3Q13 YTD £m |
Restated2 4Q13 YTD £m |
1Q14 YTD £m |
Sterling % |
Local currency % |
United Kingdom |
114 |
224 |
326 |
469 |
89 |
(22)% |
(22)% |
Ireland |
- |
2 |
4 |
8 |
3 |
- |
- |
United Kingdom & Ireland |
114 |
226 |
330 |
477 |
92 |
(19)% |
(19)% |
France |
41 |
90 |
118 |
172 |
54 |
31% |
34% |
Poland4 |
10 |
21 |
34 |
51 |
21 |
102% |
108% |
Italy - excluding Eurovita |
10 |
18 |
25 |
43 |
15 |
55% |
59% |
Spain - excluding Aseval |
3 |
11 |
17 |
31 |
8 |
129% |
135% |
Turkey |
10 |
20 |
28 |
37 |
6 |
(39)% |
(21)% |
Other Europe |
1 |
1 |
1 |
1 |
- |
(100)% |
(100)% |
Europe |
75 |
161 |
223 |
335 |
104 |
37% |
45% |
Asia - excluding Malaysia |
19 |
41 |
71 |
103 |
32 |
80% |
96% |
Value of new business - excluding Eurovita, Aseval & Malaysia |
208 |
428 |
624 |
915 |
228 |
10% |
13% |
Eurovita, Aseval & Malaysia |
1 |
(2) |
(5) |
(11) |
(4) |
- |
- |
Total value of new business |
209 |
426 |
619 |
904 |
224 |
7% |
10% |
1 Following the announced disposal of US Life in Q4 2012, it was no longer managed on a MCEV basis and it was no longer included in covered business. The sale of US Life was completed on 2 October 2013.
2 Comparatives have been restated to reflect the changes in MCEV methodology set out in note 1.
3 Currency movements are calculated using unrounded numbers so minor rounding differences may exist.
4 Poland includes Lithuania.
3 - Trend analysis of VNB (continuing operations1) - discrete
|
|
|
|
|
|
|
Growth3 on 1Q13 |
Gross of tax and non-controlling interests |
Restated2 1Q13 Discrete £m |
Restated2 2Q13 Discrete £m |
Restated2 3Q13 Discrete £m |
Restated2 4Q13 Discrete £m |
1Q14 Discrete £m |
Sterling % |
Local currency % |
United Kingdom |
114 |
110 |
102 |
143 |
89 |
(22)% |
(22)% |
Ireland |
- |
2 |
2 |
4 |
3 |
- |
- |
United Kingdom & Ireland |
114 |
112 |
104 |
147 |
92 |
(19)% |
(19)% |
France |
41 |
49 |
28 |
54 |
54 |
31% |
34% |
Poland4 |
10 |
11 |
13 |
17 |
21 |
102% |
108% |
Italy - excluding Eurovita |
10 |
8 |
7 |
18 |
15 |
55% |
59% |
Spain - excluding Aseval |
3 |
8 |
6 |
14 |
8 |
129% |
135% |
Turkey |
10 |
10 |
8 |
9 |
6 |
(39)% |
(21)% |
Other Europe |
1 |
- |
- |
- |
- |
(100)% |
(100)% |
Europe |
75 |
86 |
62 |
112 |
104 |
37% |
45% |
Asia - excluding Malaysia |
19 |
22 |
30 |
32 |
32 |
80% |
96% |
Value of new business - excluding Eurovita, Aseval & Malaysia |
208 |
220 |
196 |
291 |
228 |
10% |
13% |
Eurovita, Aseval & Malaysia |
1 |
(3) |
(3) |
(6) |
(4) |
- |
- |
Total value of new business |
209 |
217 |
193 |
285 |
224 |
7% |
10% |
1 Following the announced disposal of US Life in Q4 2012, it was no longer managed on a MCEV basis and it was no longer included in covered business. The sale of US Life was completed on 2 October 2013.
2 Comparatives have been restated to reflect the changes in MCEV methodology set out in note 1.
3 Currency movements are calculated using unrounded numbers so minor rounding differences may exist.
4 Poland includes Lithuania.
Page 8
4 - Trend analysis of PVNBP (continuing operations1) - cumulative
|
|
|
|
|
|
|
Growth on 1Q13 |
Present value of new business premiums2 |
Restated3 1Q13 YTD £m |
Restated3 2Q13 YTD £m |
Restated3 3Q13 YTD £m |
Restated3 4Q13 YTD £m |
1Q14 YTD £m |
Sterling % |
Local currency % |
|
|
|
|
|
|
|
|
United Kingdom |
2,779 |
5,560 |
8,556 |
11,924 |
2,931 |
5% |
5% |
Ireland |
117 |
225 |
338 |
469 |
105 |
(10)% |
(8)% |
United Kingdom & Ireland |
2,896 |
5,785 |
8,894 |
12,393 |
3,036 |
5% |
5% |
France |
1,243 |
2,363 |
3,367 |
4,498 |
1,310 |
5% |
8% |
Poland4 |
123 |
227 |
358 |
486 |
234 |
90% |
97% |
Italy - excluding Eurovita |
563 |
1,198 |
1,591 |
1,975 |
698 |
24% |
27% |
Spain - excluding Aseval |
301 |
547 |
719 |
1,130 |
283 |
(6)% |
(3)% |
Turkey |
135 |
253 |
341 |
524 |
110 |
(19)% |
7% |
Other Europe |
20 |
20 |
20 |
20 |
- |
(100)% |
(100)% |
Europe |
2,385 |
4,608 |
6,396 |
8,633 |
2,635 |
10% |
15% |
Asia - excluding Malaysia |
472 |
845 |
1,290 |
1,724 |
471 |
- |
8% |
Other business5 |
4 |
7 |
28 |
58 |
5 |
25% |
25% |
Total - excluding Eurovita, Aseval & Malaysia |
5,757 |
11,245 |
16,608 |
22,808 |
6,147 |
7% |
9% |
Eurovita, Aseval & Malaysia |
141 |
217 |
269 |
369 |
73 |
(48)% |
(46)% |
Total |
5,898 |
11,462 |
16,877 |
23,177 |
6,220 |
5% |
8% |
1 Following the announced disposal of US Life in Q4 2012, it was no longer managed on a MCEV basis and it was no longer included in covered business. The sale of US Life was completed on 2 October 2013.
2 Present value of new business premiums (PVNBP) is the present value of new regular premiums plus 100% of single premiums, calculated using assumptions consistent with those used to determine the value of new business.
3 Comparatives have been restated to reflect the changes in MCEV methodology set out in note 1.
4 Poland includes Lithuania.
5 Other business represents the results of Aviva Investors Pooled Pensions.
5 - Trend analysis of PVNBP (continuing operations1) - discrete
|
|
|
|
|
|
|
Growth on 1Q13 |
Present value of new business premiums2 |
Restated3 1Q13 Discrete £m |
Restated3 2Q13 Discrete £m |
Restated3 3Q13 Discrete £m |
Restated3 4Q13 Discrete £m |
1Q14 Discrete £m |
Sterling % |
Local currency % |
|
|
|
|
|
|
|
|
United Kingdom |
2,779 |
2,781 |
2,996 |
3,368 |
2,931 |
5% |
5% |
Ireland |
117 |
108 |
113 |
131 |
105 |
(10)% |
(8)% |
United Kingdom & Ireland |
2,896 |
2,889 |
3,109 |
3,499 |
3,036 |
5% |
5% |
France |
1,243 |
1,120 |
1,004 |
1,131 |
1,310 |
5% |
8% |
Poland4 |
123 |
104 |
131 |
128 |
234 |
90% |
97% |
Italy - excluding Eurovita |
563 |
635 |
393 |
384 |
698 |
24% |
27% |
Spain - excluding Aseval |
301 |
246 |
172 |
411 |
283 |
(6)% |
(3)% |
Turkey |
135 |
118 |
88 |
183 |
110 |
(19)% |
7% |
Other Europe |
20 |
- |
- |
- |
- |
(100)% |
(100)% |
Europe |
2,385 |
2,223 |
1,788 |
2,237 |
2,635 |
10% |
15% |
Asia - excluding Malaysia |
472 |
373 |
445 |
434 |
471 |
- |
8% |
Other business5 |
4 |
3 |
21 |
30 |
5 |
25% |
25% |
Total - excluding Eurovita, Aseval & Malaysia |
5,757 |
5,488 |
5,363 |
6,200 |
6,147 |
7% |
9% |
Eurovita, Aseval & Malaysia |
141 |
76 |
52 |
100 |
73 |
(48)% |
(46)% |
Total |
5,898 |
5,564 |
5,415 |
6,300 |
6,220 |
5% |
8% |
1 Following the announced disposal of US Life in Q4 2012, it was no longer managed on a MCEV basis and it was no longer included in covered business. The sale of US Life was completed on 2 October 2013.
2 Present value of new business premiums (PVNBP) is the present value of new regular premiums plus 100% of single premiums, calculated using assumptions consistent with those used to determine the value of new business.
3 Comparatives have been restated to reflect the changes in MCEV methodology set out in note 1.
4 Poland includes Lithuania.
5 Other business represents the results of Aviva Investors Pooled Pensions.
Page 9
6 - Trend analysis of PVNBP by product (continuing operations1) - cumulative
|
|
|
|
|
|
|
Growth on 1Q13 |
Present value of new business premiums2 |
Restated3 1Q13 YTD £m |
Restated3 2Q13 YTD £m |
Restated3 3Q13 YTD £m |
Restated3 4Q13 YTD £m |
1Q14 YTD £m |
Sterling % |
Local currency % |
|
|
|
|
|
|
|
|
Pensions |
1,322 |
2,479 |
3,818 |
5,476 |
1,328 |
- |
- |
Annuities |
630 |
1,217 |
1,664 |
2,327 |
500 |
(21)% |
(21)% |
Bonds |
33 |
59 |
97 |
183 |
45 |
36% |
36% |
Protection |
253 |
504 |
781 |
992 |
297 |
17% |
17% |
Equity release |
98 |
182 |
297 |
401 |
117 |
19% |
19% |
Other4 |
443 |
1,119 |
1,899 |
2,545 |
644 |
45% |
45% |
United Kingdom |
2,779 |
5,560 |
8,556 |
11,924 |
2,931 |
5% |
5% |
Ireland |
117 |
225 |
338 |
469 |
105 |
(10)% |
(8)% |
United Kingdom & Ireland |
2,896 |
5,785 |
8,894 |
12,393 |
3,036 |
5% |
5% |
Savings |
1,173 |
2,229 |
3,197 |
4,278 |
1,232 |
5% |
8% |
Protection |
70 |
134 |
170 |
220 |
78 |
11% |
13% |
France |
1,243 |
2,363 |
3,367 |
4,498 |
1,310 |
5% |
8% |
Pensions |
224 |
385 |
549 |
881 |
308 |
38% |
61% |
Savings |
769 |
1,560 |
2,069 |
2,702 |
893 |
16% |
19% |
Annuities |
6 |
11 |
14 |
23 |
2 |
(67)% |
(71)% |
Protection5 |
143 |
289 |
397 |
529 |
122 |
(15)% |
(9)% |
Poland6, Italy6, Spain6 and Other |
1,142 |
2,245 |
3,029 |
4,135 |
1,325 |
16% |
23% |
Europe |
2,385 |
4,608 |
6,396 |
8,633 |
2,635 |
10% |
15% |
Asia - excluding Malaysia |
472 |
845 |
1,290 |
1,724 |
471 |
- |
8% |
Other business7 |
4 |
7 |
28 |
58 |
5 |
25% |
25% |
Total - excluding Eurovita, Aseval & Malaysia |
5,757 |
11,245 |
16,608 |
22,808 |
6,147 |
7% |
9% |
Eurovita, Aseval & Malaysia |
141 |
217 |
269 |
369 |
73 |
(48)% |
(46)% |
Total |
5,898 |
11,462 |
16,877 |
23,177 |
6,220 |
5% |
8% |
1 Following the announced disposal of US Life in Q4 2012, it was no longer managed on a MCEV basis and it was no longer included in covered business. The sale of US Life was completed on 2 October 2013.
2 Present value of new business premiums (PVNBP) is the present value of new regular premiums plus 100% of single premiums, calculated using assumptions consistent with those used to determine the value of new business.
3 Comparatives have been restated to reflect the changes in MCEV methodology set out in note 1.
4 Other UK business includes UK Retail Fund Management and UK long term health business.
5 Subsequent to FY13 a whole of life unit-linked protection product in Poland was reclassified from savings to protection business. As a result, Poland protection PVNBP has increased £25m in 1Q13 YTD, £77m in 2Q13 YTD, £91m in 3Q13 YTD and £205m in 4Q13 YTD with an equal and opposite movement in Poland savings PVNBP.
6 Poland includes Lithuania, Italy excludes Eurovita, Spain excludes Aseval.
7 Other business represents the results of Aviva Investors Pooled Pensions.
7 - Trend analysis of PVNBP by product (continuing operations1) - discrete
|
|
|
|
|
|
|
Growth on 1Q13 |
Present value of new business premiums2 |
Restated3 1Q13 Discrete £m |
Restated3 2Q13 Discrete £m |
Restated3 3Q13 Discrete £m |
Restated3 4Q13 Discrete £m |
1Q14 Discrete £m |
Sterling % |
Local currency % |
|
|
|
|
|
|
|
|
Pensions |
1,322 |
1,157 |
1,339 |
1,658 |
1,328 |
- |
- |
Annuities |
630 |
587 |
447 |
663 |
500 |
(21)% |
(21)% |
Bonds |
33 |
26 |
38 |
86 |
45 |
36% |
36% |
Protection |
253 |
251 |
277 |
211 |
297 |
17% |
17% |
Equity release |
98 |
84 |
115 |
104 |
117 |
19% |
19% |
Other4 |
443 |
676 |
780 |
646 |
644 |
45% |
45% |
United Kingdom |
2,779 |
2,781 |
2,996 |
3,368 |
2,931 |
5% |
5% |
Ireland |
117 |
108 |
113 |
131 |
105 |
(10)% |
(8)% |
United Kingdom & Ireland |
2,896 |
2,889 |
3,109 |
3,499 |
3,036 |
5% |
5% |
Savings |
1,173 |
1,056 |
968 |
1,081 |
1,232 |
5% |
8% |
Protection |
70 |
64 |
36 |
50 |
78 |
11% |
13% |
France |
1,243 |
1,120 |
1,004 |
1,131 |
1,310 |
5% |
8% |
Pensions |
224 |
161 |
164 |
332 |
308 |
38% |
61% |
Savings |
769 |
791 |
509 |
633 |
893 |
16% |
19% |
Annuities |
6 |
5 |
3 |
9 |
2 |
(67)% |
(71)% |
Protection5 |
143 |
146 |
108 |
132 |
122 |
(15)% |
(9)% |
Poland6, Italy6, Spain6 and Other |
1,142 |
1,103 |
784 |
1,106 |
1,325 |
16% |
23% |
Europe |
2,385 |
2,223 |
1,788 |
2,237 |
2,635 |
10% |
15% |
Asia - excluding Malaysia |
472 |
373 |
445 |
434 |
471 |
- |
8% |
Other business7 |
4 |
3 |
21 |
30 |
5 |
25% |
25% |
Total - excluding Eurovita, Aseval & Malaysia |
5,757 |
5,488 |
5,363 |
6,200 |
6,147 |
7% |
9% |
Eurovita, Aseval & Malaysia |
141 |
76 |
52 |
100 |
73 |
(48)% |
(46)% |
Total |
5,898 |
5,564 |
5,415 |
6,300 |
6,220 |
5% |
8% |
1 Following the announced disposal of US Life in Q4 2012, it was no longer managed on a MCEV basis and it was no longer included in covered business. The sale of US Life was completed on 2 October 2013.
2 Present value of new business premiums (PVNBP) is the present value of new regular premiums plus 100% of single premiums, calculated using assumptions consistent with those used to determine the value of new business.
3 Comparatives have been restated to reflect the changes in MCEV methodology set out in note 1.
4 Other UK business includes UK Retail Fund Management and UK long term health business.
5 Subsequent to FY13 a whole of life unit-linked protection product in Poland was reclassified from savings to protection business. As a result, Poland protection PVNBP has increased £25m in 1Q13, £52m in 2Q13, £14m in 3Q13 and £114m in 4Q13 with an equal and opposite movement in Poland savings PVNBP.
6 Poland includes Lithuania, Italy excludes Eurovita, Spain excludes Aseval.
7 Other business represents the results of Aviva Investors Pooled Pensions.
Page 10
8 - Geographical analysis of regular and single premiums (continuing operations1)
|
|
|
|
|
|
|
Regular premiums |
|
|
Single premiums |
|
3 months 2014 £m |
Local currency growth |
WACF |
Present value £m |
Restated2 3 months 2013 £m |
WACF |
Present value £m |
3 months 2014 £m |
Restated2 3 months 2013 £m |
Local currency growth |
United Kingdom |
243 |
12% |
5.0 |
1,203 |
217 |
4.9 |
1,056 |
1,728 |
1,723 |
- |
Ireland |
7 |
17% |
4.6 |
32 |
6 |
4.7 |
28 |
73 |
89 |
(15)% |
United Kingdom & Ireland |
250 |
12% |
4.9 |
1,235 |
223 |
4.9 |
1,084 |
1,801 |
1,812 |
- |
France |
26 |
(4)% |
7.8 |
202 |
27 |
8.2 |
222 |
1,108 |
1,021 |
11% |
Poland3 |
19 |
58% |
10.7 |
204 |
12 |
8.3 |
99 |
30 |
24 |
30% |
Italy - excluding Eurovita |
19 |
(5)% |
5.0 |
95 |
21 |
5.2 |
109 |
603 |
454 |
36% |
Spain - excluding Aseval |
11 |
(8)% |
5.2 |
57 |
12 |
5.9 |
71 |
226 |
230 |
1% |
Turkey |
27 |
23% |
3.6 |
98 |
28 |
4.2 |
117 |
12 |
18 |
(14)% |
Other Europe |
- |
(100)% |
- |
- |
4 |
1.5 |
6 |
- |
14 |
(100)% |
Europe |
102 |
6% |
6.4 |
656 |
104 |
6.0 |
624 |
1,979 |
1,761 |
16% |
Asia - excluding Malaysia |
69 |
- |
5.7 |
390 |
74 |
5.6 |
415 |
81 |
57 |
50% |
Other business4 |
- |
- |
- |
- |
- |
- |
- |
5 |
4 |
25% |
Total - excluding Eurovita, Aseval & Malaysia |
421 |
9% |
5.4 |
2,281 |
401 |
5.3 |
2,123 |
3,866 |
3,634 |
8% |
Eurovita, Aseval & Malaysia |
1 |
(88)% |
7.0 |
7 |
8 |
4.8 |
38 |
66 |
103 |
(34)% |
Total |
422 |
7% |
5.4 |
2,288 |
409 |
5.3 |
2,161 |
3,932 |
3,737 |
7% |
1 Following the announced disposal of US Life in Q3 2012, it was no longer managed on a MCEV basis and it was no longer included in covered business. The sale of US Life was completed on 2 October 2013.
2 Comparatives have been restated to reflect the changes in MCEV methodology set out in note 1.
3 Poland includes Lithuania.
4 Other business represents the results of Aviva Investors Pooled Pensions.
9 - Trend analysis of investment sales - cumulative
|
|
|
|
|
|
|
Growth on 1Q13 |
Investment sales1 |
1Q13 YTD £m |
2Q13 YTD £m |
3Q13 YTD £m |
4Q13 YTD £m |
1Q14 YTD £m |
Sterling % |
Local currency % |
United Kingdom & Ireland2 |
305 |
841 |
1,494 |
2,040 |
486 |
59% |
59% |
Aviva Investors |
787 |
1,563 |
2,100 |
2,683 |
730 |
(7)% |
(4)% |
Asia |
42 |
94 |
124 |
152 |
36 |
(14)% |
(8)% |
Total investment sales |
1,134 |
2,498 |
3,718 |
4,875 |
1,252 |
10% |
13% |
1 Investment sales are calculated as new single premiums plus the annualised value of new regular premiums.
2 UK & Ireland investment sales are also reported in UK Life PVNBP following the extension of MCEV covered business. See note 1 for details.
10 - Trend analysis of investment sales - discrete
|
|
|
|
|
|
|
Growth on 1Q13 |
Investment sales1 |
1Q13 Discrete £m |
2Q13 Discrete £m |
3Q13 Discrete £m |
4Q13 Discrete £m |
1Q14 Discrete £m |
Sterling % |
Local currency % |
United Kingdom & Ireland2 |
305 |
536 |
653 |
546 |
486 |
59% |
59% |
Aviva Investors |
787 |
776 |
537 |
583 |
730 |
(7)% |
(4)% |
Asia |
42 |
52 |
30 |
28 |
36 |
(14)% |
(8)% |
Total investment sales |
1,134 |
1,364 |
1,220 |
1,157 |
1,252 |
10% |
13% |
1 Investment sales are calculated as new single premiums plus the annualised value of new regular premiums.
2 UK & Ireland investment sales are also reported in UK Life PVNBP following the extension of MCEV covered business. See note 1 for details.
11 - Geographical analysis of regular and single premiums - investment sales
|
|
|
Regular |
|
|
Single |
PVNBP |
Investment sales1 |
3 months 2014 £m |
3 months 2013 £m |
Local currency growth |
3 months 2014 £m |
3 months 2013 £m |
Local currency growth |
Local currency growth |
United Kingdom & Ireland2 |
5 |
3 |
67% |
481 |
302 |
59% |
59% |
Aviva Investors |
2 |
2 |
100% |
728 |
785 |
(4)% |
(4)% |
Asia |
- |
- |
- |
36 |
42 |
(8)% |
(8)% |
Total investment sales |
7 |
5 |
75% |
1,245 |
1,129 |
13% |
13% |
1 Investment sales are calculated as new single premiums plus the annualised value of new regular premiums.
2 UK & Ireland investment sales are also reported in UK Life PVNBP following the extension of MCEV covered business. See note 1 for details.
Page 11
12 - Trend analysis of general insurance and health net written premiums - cumulative
|
|
|
|
|
|
|
Growth on 1Q13 YTD |
|
1Q13 YTD £m |
2Q13 YTD £m |
3Q13 YTD £m |
4Q13 YTD £m |
1Q14 YTD £m |
Sterling % |
Local currency % |
General insurance |
|
|
|
|
|
|
|
United Kingdom |
923 |
1,963 |
2,904 |
3,823 |
845 |
(8)% |
(8)% |
Ireland |
71 |
146 |
215 |
278 |
65 |
(8)% |
(6)% |
United Kingdom & Ireland |
994 |
2,109 |
3,119 |
4,101 |
910 |
(8)% |
(8)% |
Europe |
435 |
764 |
1,033 |
1,360 |
440 |
1% |
5% |
Canada |
470 |
1,126 |
1,718 |
2,250 |
426 |
(9)% |
5% |
Asia |
3 |
7 |
11 |
14 |
3 |
- |
50% |
Other |
20 |
20 |
21 |
33 |
4 |
(80)% |
(80)% |
|
1,922 |
4,026 |
5,902 |
7,758 |
1,783 |
(7)% |
(3)% |
Health insurance |
|
|
|
|
|
|
|
United Kingdom1 |
138 |
289 |
383 |
536 |
144 |
4% |
4% |
Ireland |
36 |
52 |
71 |
99 |
33 |
(8)% |
(6)% |
United Kingdom & Ireland |
174 |
341 |
454 |
635 |
177 |
2% |
2% |
Europe |
89 |
135 |
179 |
241 |
94 |
6% |
9% |
Asia2 |
35 |
47 |
69 |
86 |
29 |
(17)% |
(3)% |
|
298 |
523 |
702 |
962 |
300 |
1% |
4% |
Total |
2,220 |
4,549 |
6,604 |
8,720 |
2,083 |
(6)% |
(2)% |
1 These premiums are also reported in UK Life PVNBP following the extension of MCEV covered business (see note 1 for details). 1Q13 NWP of £138 million, 2Q13 YTD NWP of £289 million, 3Q13 YTD NWP of £383 million, FY 2013 NWP of £536 million and 1Q14 NWP of £144 million are respectively equivalent to £138 million, £278 million, £405 million, £505 million and £158 million on a PVNBP basis.
2 Singapore long term health business is also reported in Asia PVNBP following the extension of MCEV covered business (see note 1 for details). For Singapore long term health business, 3Q13 YTD NWP of £5 million, FY 2013 NWP of £11 million and 1Q14 NWP of £5 million are respectively equivalent to £47 million, £97 million and £37 million on a PVNBP basis.
13 - Trend analysis of general insurance and health net written premiums - discrete
|
|
|
|
|
|
|
Growth on 1Q13 YTD |
|
1Q13 Discrete £m |
2Q13 Discrete £m |
3Q13 Discrete £m |
4Q13 Discrete £m |
1Q14 Discrete £m |
Sterling % |
Local currency % |
General insurance |
|
|
|
|
|
|
|
United Kingdom |
923 |
1,040 |
941 |
919 |
845 |
(8)% |
(8)% |
Ireland |
71 |
75 |
69 |
63 |
65 |
(8)% |
(6)% |
United Kingdom & Ireland |
994 |
1,115 |
1,010 |
982 |
910 |
(8)% |
(8)% |
Europe |
435 |
329 |
269 |
327 |
440 |
1% |
5% |
Canada |
470 |
656 |
592 |
532 |
426 |
(9)% |
5% |
Asia |
3 |
4 |
4 |
3 |
3 |
- |
50% |
Other |
20 |
- |
1 |
12 |
4 |
(80)% |
(80)% |
|
1,922 |
2,104 |
1,876 |
1,856 |
1,783 |
(7)% |
(3)% |
Health insurance |
|
|
|
|
|
|
|
United Kingdom1 |
138 |
151 |
94 |
153 |
144 |
4% |
4% |
Ireland |
36 |
16 |
19 |
28 |
33 |
(8)% |
(6)% |
United Kingdom & Ireland |
174 |
167 |
113 |
181 |
177 |
2% |
2% |
Europe |
89 |
46 |
44 |
62 |
94 |
6% |
9% |
Asia2 |
35 |
12 |
22 |
17 |
29 |
(17)% |
(3)% |
|
298 |
225 |
179 |
260 |
300 |
1% |
4% |
Total |
2,220 |
2,329 |
2,055 |
2,116 |
2,083 |
(6)% |
(2)% |
1 These premiums are also reported in UK Life PVNBP following the extension of MCEV covered business (see note 1 for details). 1Q13 NWP of £138 million, 2Q13 NWP of £151 million, 3Q13 NWP of £94 million, 4Q13 NWP of £153 million and 1Q14 NWP of £144 million are respectively equivalent to £138 million, £140 million, £127 million, £100 million and £158 million on a PVNBP basis.
2 Singapore long term health business is also reported in Asia PVNBP following the extension of MCEV covered business (see note 1 for details). For Singapore long term health business, 3Q13 NWP of £5 million, 4Q13 NWP of £6 million and 1Q14 NWP of £5 million are respectively equivalent to £47 million, £50 million and £37 million on a PVNBP basis.
END